Published in Mol Ther on September 12, 2013
Trial Watch:: Oncolytic viruses for cancer therapy. Oncoimmunology (2014) 1.22
Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer. Front Oncol (2014) 0.85
Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies. Biomedicines (2017) 0.79
High-throughput screening to enhance oncolytic virus immunotherapy. Oncolytic Virother (2016) 0.77
Big Data Offers Novel Insights for Oncolytic Virus Immunotherapy. Viruses (2016) 0.75
Replicon RNA Viral Vectors as Vaccines. Vaccines (Basel) (2016) 0.75
Oncolytic Alphaviruses in Cancer Immunotherapy. Vaccines (Basel) (2017) 0.75
Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature (2001) 25.15
Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity (2003) 21.56
The alphaviruses: gene expression, replication, and evolution. Microbiol Rev (1994) 16.68
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A (1994) 8.92
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res (2009) 6.83
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med (1999) 6.09
Oncolytic virotherapy. Nat Biotechnol (2012) 5.79
Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol (2002) 5.75
Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol (2000) 5.45
Tumors of the mediastinum. Chest (2005) 5.12
Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice. Immunity (1994) 5.06
Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs. J Virol (1993) 4.19
Patterns of lymphatic drainage in the adult laboratory rat. J Anat (1971) 4.15
Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol (2007) 3.86
Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol (2002) 3.63
Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo. Nat Immunol (2002) 3.22
Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res (2007) 2.72
Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res (2011) 2.63
Oncolytic viruses in cancer therapy. Cancer Lett (2007) 2.45
Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res (2003) 2.33
CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res (2011) 2.26
Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes. J Immunol (1993) 2.25
The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci U S A (1996) 2.24
Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res (2010) 2.19
The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther (2009) 2.14
Antigen processing in vivo and the elicitation of primary CTL responses. J Immunol (1995) 2.12
In vivo bioluminescence imaging for integrated studies of infection. Cell Microbiol (2004) 1.89
Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med (2002) 1.88
Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein. J Virol (2000) 1.52
Murine cytomegalovirus displays selective infection of cells within hours after systemic administration. J Gen Virol (2009) 1.40
Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res (2010) 1.38
Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res (2000) 1.35
Systemic tumor targeting and killing by Sindbis viral vectors. Nat Biotechnol (2003) 1.31
Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther (2002) 1.29
Strategies for cancer vaccine development. J Biomed Biotechnol (2010) 1.26
Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice. J Virol (1998) 1.25
Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther (2002) 1.17
Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res (1999) 1.16
Using sindbis viral vectors for specific detection and suppression of advanced ovarian cancer in animal models. Cancer Res (2004) 1.09
Metastatic pattern of CC531 colon carcinoma cells in the abdominal cavity: an experimental model of peritoneal carcinomatosis in rats. Eur J Surg Oncol (2001) 0.94
Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo. Mol Ther (2011) 0.94
In vivo antitumor activity of Sindbis viral vectors. J Natl Cancer Inst (2002) 0.90
Resistance to two heterologous neurotropic oncolytic viruses, Semliki Forest virus and vaccinia virus, in experimental glioma. J Virol (2012) 0.84
Activation of cytotoxic and regulatory functions of NK cells by Sindbis viral vectors. PLoS One (2011) 0.83